

# Chiara Cc Carcieri

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7138742/chiara-cc-carcieri-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19  
papers

324  
citations

9  
h-index

18  
g-index

19  
ext. papers

408  
ext. citations

3.5  
avg, IF

2.82  
L-index

#	Paper	IF	Citations
19	A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 125, 369-75	3.5	96
18	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , <b>2018</b> , 70, 143-149	4.8	40
17	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 138, 223-230	3.5	34
16	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3061-6	5.1	34
15	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 197-203	3.8	23
14	A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2015</b> , 114, 8-11	3.5	17
13	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2017</b> , 44, 1083-1088	3	13
12	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , <b>2017</b> , 5,	4.8	12
11	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 913-925	2.6	10
10	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , <b>2017</b> , 45, 103-106	5.8	9
9	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 307-10	1.9	8
8	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 81, 615-620	3.5	7
7	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1659-1664	5.1	6
6	Influence of ABCB11 and HNF4B genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2846-2849	5.1	6
5	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 651-661	2.6	5
4	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , <b>2018</b> , 60, 42-47	4.5	2
3	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 705-708	3.3	1

2	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 607-611	2.6	1
1	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 701-707	2.6	0